Login to Your Account

Corrections & Clarifications

Friday, January 14, 2011
An item in BioWorld Today, Jan. 12, 2011, should have stated that Astex Therapeutics Ltd., of Cambridge, UK, received an undisclosed milestone payment from Novartis AG triggered by the initiation of a clinical trial of LEE011, an oncology candidate being developed by the companies under a 2005 collaboration aimed at cell cycle inhibitors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription